←
Marc Braunstein, MD, PhD, FACP, FASCO1,534 posts
Marc Braunstein, MD, PhD, FACP, FASCO avatar✓

Marc Braunstein, MD, PhD, FACP, FASCO ✓

@docbraunstein

Hematologist/Oncologist and @nyulisom_hemonc Fellowship Program Director @nyulangoneli #hemeonc #multiplemyeloma #myeloma #mmsm #lymphoma. Tweets are my own.

◷ Joined February 2014▧ 172 Photos and videos
Marc Braunstein, MD, PhD, FACP, FASCO avatar
Marc Braunstein, MD, PhD, FACP, FASCO@docbraunstein·20 Feb 2022

In #myeloma, why do we perform an SPEP using serum and not plasma? Serum = plasma minus clotting factors. A plasma protein electrophoresis (show below) might obscure a monoclonal protein due to clotting factors such as fibrinogen. (Ref: Clinical Immunology 3rd Ed, Chapter 96)

Post attachment
Al-Ola A Abdallah MD (USMIRC) avatar
⟳ Marc Braunstein, MD, PhD, FACP, FASCO retweeted
Al-Ola A Abdallah MD (USMIRC)@Abdallah81MD·Nov 12

Here are the top 11 abstracts and (all were scored fairly) at #ASH2026 that I believe will show main impact : 1. AQUILA · Abstract #112 · 9.8/10 1/3 Does treating high-risk smoldering myeloma help patients live longer? My #1 #ASH26 abstract is AQUILA (#112), daratumumab vs active monitoring in high-risk SMM. My score: 9.8/10. 2/3 Among 390 randomized patients, 7-year overall survival was 87.8% with daratumumab vs 78.7% with monitoring. That’s a 9.1-point absolute difference. Median PFS was 82.5 vs 34.9 months. 3/3 This changes my conversation with an asymptomatic patient. Once we confirm high-risk SMM and exclude active myeloma, we can weigh up to 3 years of treatment against a measurable survival benefit. #mmsm #myeloma #USMIRC #MedEd #medtwitter @USMIRCNEWS @US_HMC @Larvol @OpenMedKate @oncodaily

Post attachmentPost attachment
Samer Al Hadidi, MD,MS,FACP avatar
⟳ Marc Braunstein, MD, PhD, FACP, FASCO retweeted
Samer Al Hadidi, MD,MS,FACP@HadidiSamer·Nov 11

My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer 1⃣MonumenTAL-6: Tec+Tal and Tal+Pom vs EPd/PVd ➡️Phase III, RRMM after 1–4 prior lines, all exposed to anti-CD38 and lenalidomide (80% anti-CD38-refractory) ➡️n=838; median FU: 13.4 mo ➡️Tec+Tal improved PFS HR 0.11; 12-mo PFS 89% vs 30%) and OS (HR 0.38; 12-mo OS 91% vs 80%). Tal+Pom also better than control arm (PFS HR 0.27, OS HR 0.55). 🛑Grade 3/4 infections were 312% with Tec+Tal vs 25% with control (92% of patients needed IVIG), ICANS 6%, taste changes 76% and weight loss 41% (Only 6% stopped treatment for AEs) Time limited therapy with dual targeting in pts after anti-CD38/len failure

Post attachment
Robert Z. Orlowski avatar
⟳ Marc Braunstein, MD, PhD, FACP, FASCO retweeted
Robert Z. Orlowski@Myeloma_Doc·Nov 10

#Myeloma Paper of the Day: Modeling of long-term PFS in NDMM treated w/ Dara-VRd on PERSEUS (TE pts) finds 158-255 months (VRd 76-119 mos) while for CEPHEUS (TIE pts) projected median PFS range across distributions was 96-118 (VRd 52-54 mos): pubmed.ncbi.nlm.nih.gov/4300…. #mmsm

Post attachmentPost attachmentPost attachmentPost attachment
OncLive.com avatar
⟳ Marc Braunstein, MD, PhD, FACP, FASCO retweeted
OncLive.com@OncLive·Oct 16

Nearly half of patients with CLL develop a serious infection, and infection contributes to almost a third of deaths. Danielle M. Brander, MD, and Marc J. Braunstein, MD, PhD, on why that risk should shape frontline therapy choice. Explore the OncLive® News Network series: hubs.li/Q04Br9wf0 @dbranderMD @DukeHealth @docbraunstein @NYULISOM_HemOnc #leusm #CLL

0:19
Ankit kansagra avatar
⟳ Marc Braunstein, MD, PhD, FACP, FASCO retweeted
Ankit kansagra@kansagraMD·Oct 8

Annual MRD testing is now in the NCCN myeloma guidelines. Recent version 1.2027 lays out bone marrow MRD by NGS (FDA-approved assay) or multicolor flow across the whole course of treatment: after induction, at 100 days or 3 months after transplant or CAR-T, after relapse therapy or a major Tx change, and at regular intervals during maintenance or surveillance. 10^-6 is preferred, 10^-5 is the minimum. A baseline clonotype sample goes in once, at diagnosis or before Tx. And the line that will change clinic workflow: "annual testing is the general recommendation." Quick thoughts - Sustained MRD negativity tells us far more than a single negative result, and you can't know it's sustained without serial testing - The baseline clonotype sample is the step most likely to get missed. If nobody sends it at diagnosis, NGS tracking gets much harder later, often waiting on a relapse sample. That's an operational fix: build it into the diagnostic marrow order set - For EMD, PCL and oligo- or non-secretory disease, MRD supplements imaging (and circulating plasma cells in PCL) rather than replacing it. Good that this is spelled out - A marrow every year is real burden for pts, and for practices that don't have a procedure slot or a payer who agrees - The bigger gap is translational. We have a schedule for measuring MRD, but outside trials we still don't have validated rules for what to do with the result: when to stop maintenance, when to escalate on MRD resurfacing An important step in right direction, but much more to do for implementing in beyond academic practices. #MultipleMyeloma #mmsm #MRD

Hamza Hashmi avatar
⟳ Marc Braunstein, MD, PhD, FACP, FASCO retweeted
Hamza Hashmi@hhashmi87·Sep 25

PERSEUS long-term follow-up at #IMS26: D-VRd → DR vs VRd → R in transplant-eligible NDMM (median follow-up >80 mo) 💡72-mo PFS: 81% vs 56% 💡Median PFS: not reached vs 80 mo 💡The benefit held across risk groups: 🟢 Standard risk: 88% vs 63% (HR 0.27) 🔴 High risk: 55.0% vs 33% (HR 0.55) 💡MRDneg ~60-65% at 2 yr and 3 yr Exceptional outcomes with QUADs, highlighting potential to stop maintenance for standard risk at 2yrs. High-risk MM still needs better options #IMS26 @Myeloma_Society

Post attachmentPost attachmentPost attachment